Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Paulina D HortonDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-5190-569X
Alina SyedDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0009-0006-9517-4012
Michelle WinklerDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0001-8522-1272
Abishek B VaidyaCenter for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston , Houston, TX, USA.ORCID 0000-0001-8458-7950
Michael RaridenCenter for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston , Houston, TX, USA.ORCID 0000-0002-4328-1004
Neha AroraDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0001-9198-8744
Yong ZhouDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-0214-8151
Michihiro KobayashiCenter for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston , Houston, TX, USA.ORCID 0000-0001-6065-6026
Momoko YoshimotoCenter for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston , Houston, TX, USA.ORCID 0000-0002-7272-6682
Hyun Jung LeeDepartment of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, South Korea.ORCID 0000-0002-9941-9826
Hyun-Eui KimDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0003-1495-1993
John P HaganMolecular and Translational Biology Program, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences , Houston, TX, USA.ORCID 0000-0003-0295-4898
Catherine DenicourtDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0001-8721-0163
Travis I MooreDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-8503-6023
Pamela L WenzelDepartment of Integrative Biology & Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-4530-015X
Funding
Biomechanical Determinants of Hematopoietic Stem Cell PotentialR01DK111599 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI PAMELA LYNN WENZEL · 2018 to 2026
$4.2M
The developmental pathway of fetal-derived B cellsR01AI165798 · NIAID · WESTERN MICHIGAN UNIV SCHOOL OF MEDICINE · PI Nichol Elizabeth Holodick, Momoko Yoshimoto · 2023 to 2026
$2.4M
The Role of Biological Sex in the Self-renewal of B1 Cells into Old Age in Mice and HumansR01AG084752 · NIA · WESTERN MICHIGAN UNIV SCHOOL OF MEDICINE · PI Nichol Elizabeth Holodick, THOMAS L ROTHSTEIN · 2024 to 2026
$2.3M
Super Resolution 3D-STED Microscope for a Core FacilityS10OD036331 · OD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOORE, TRAVIS I · 2024 to 2024
$1.2M
Mechanoregulation of the Leukocyte Specific Integrin LFA-1 by the Actin CytoskeletonK01HL143111 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOORE, TRAVIS I · 2018 to 2022
$856k
American Society of HematologyCancer Prevention and Research Institute of Texas RP110776NHLBI NIH HHS K01 HL143111NIAID NIH HHS R01 AI165798NIA NIH HHS R01 AG084752NIDDK NIH HHS R01 DK111599NIH HHS K01HL143111NIH HHS R01DK111599NIH HHS S10 OD036331State of Texas Emerging Technology Fund
6 · The paper itself
Abstract
Mechanical force generated by blood flow stimulates emergence of the first hematopoietic stem cells (HSCs) that populate the blood system. Force drives the transition of HSC precursors from an endothelial to hematopoietic identity, yet the molecular regulation of this fate switch remains poorly understood. We report that shear stress triggers adaptation in mitochondrial composition, ultrastructure, and function, which are essential for hematopoietic fate and engraftment potential. Shear stress remodels mitochondria in hemogenic endothelium by promoting mitochondrial gene transcription and protein synthesis. Laminar flow selectively initiates translation of 5' terminal polypyrimidine (5'TOP) motif-containing transcripts, which commonly encode ribosome and translation machinery. Flow-responsive metabolic reprogramming depends upon mechanistic target of rapamycin (mTOR) activation and is stymied when ribosome activity or mTOR is blocked. Conversely, chemical induction of mTOR mimics the effects of force on mitochondria and blood reconstituting potential and also partially rescues hematopoiesis in heartbeat mutants in utero. These findings identify mechanometabolism as a determinant of hematopoietic fate that could inform engineering of HSCs for disease modeling and treatment.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Mechanometabolism instructs hematopoietic stem cell specification. · full record | Socratic